



S11 Fig. Natural killer cell responses to treatment and baseline expression of CD25 and CD122. (A) NK CD56^{dim} have a large and sustained increase as a % of lymphocytes at the highest doses of 1.0-1.5 x 10⁶ IU/m² (average baseline NK CD56^{dim} (% lymphocytes) 8.09 % SE= 0.61 range= 2.09-18.9, N=38). **(B)** NK CD56^{dim} pSTAT5 response at 90 minutes (average baseline pSTAT5 MFI 20.46 (1.2) 0-40.62, N=34). **(C)** Pre-treatment expression of CD25 and CD122 on NK CD56^{dim} and NK CD56^{bright}. **(D)** CD25 expression on NK CD56^{dim} at 90 minutes following treatment (baseline NK CD56^{dim} CD25 MFI 184 (11) 83.8-401, N=38). **(E)** Change in frequency of Ki-67⁺ NK CD56^{dim} with the greatest increase at the highest doses (1.0-1.5 x 10⁶ IU/m²) (baseline Ki-67⁺ NK CD56^{dim} 4.49 % (0.52) 1.5-13.1, N=30). **(F)** NKT response to Proleukin at 90 minutes and on following days post treatment (average baseline NKT (% lymphocytes) 2.18% SE=0.26 range=0.06-7.03, N=38). **(G)** Individual plots of NKT response in participants (grey lines) with black lines showing the mean values for each dose group